Aviva PLC Has $16.40 Million Stock Holdings in Insulet Corporation $PODD

Aviva PLC raised its holdings in Insulet Corporation (NASDAQ:PODD) by 6.7% in the 2nd quarter, HoldingsChannel reports. The fund owned 52,189 shares of the medical instruments supplier’s stock after acquiring an additional 3,282 shares during the period. Aviva PLC’s holdings in Insulet were worth $16,397,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of PODD. Sequoia Financial Advisors LLC grew its stake in shares of Insulet by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock worth $634,000 after purchasing an additional 45 shares during the last quarter. Nissay Asset Management Corp Japan ADV lifted its holdings in Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock worth $2,222,000 after buying an additional 48 shares during the period. Mather Group LLC. grew its position in shares of Insulet by 4.4% in the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after buying an additional 48 shares during the last quarter. Brooklyn Investment Group grew its position in shares of Insulet by 7.0% in the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after buying an additional 52 shares during the last quarter. Finally, Cooper Financial Group increased its stake in shares of Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after buying an additional 58 shares during the period.

Analyst Ratings Changes

A number of equities analysts recently commented on PODD shares. BTIG Research reaffirmed a “buy” rating and issued a $370.00 price objective on shares of Insulet in a research note on Thursday. JPMorgan Chase & Co. raised their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Stifel Nicolaus initiated coverage on shares of Insulet in a research note on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price objective on the stock. Barclays lifted their target price on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Wolfe Research upped their price target on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $374.10.

Insiders Place Their Bets

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by company insiders.

Insulet Trading Up 0.2%

Shares of Insulet stock opened at $320.35 on Tuesday. The stock has a market capitalization of $22.55 billion, a PE ratio of 97.37, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $353.50. The stock has a 50 day moving average price of $324.67 and a two-hundred day moving average price of $310.73. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same period in the prior year, the firm earned $1.08 earnings per share. Insulet’s revenue for the quarter was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.